John Hopkins licenses away the key antigen in GVAX vaccine to IMUC
I came across a marketing piece for the GVAX vaccine for pancreatic cancer that was presented last week at the 2012 Gastrointestinal Cancers Symposium. Dung T. Le is the lead investigator at Johns Hopkins University and It shows how the GVAX Pancreas cancer vaccine increased the median survival of pancreatic cancer patients.
What is even more interesting is that after vaccination increase in mesothelin-specific T cells in patients correlates with disease-free survival (no other antigen had any such correlation). The specific peptides for mesothelin antigen were recently licensed by IMUC for all cancer indications including ovarian and pancreatic cancers.
It seems this licensing agreement gives IMUC the most critical component of GVAX vaccine for going after pancreatic cancer. By combining mesothelin with other cancer stem cell antigens, IMUC is definitely on its way of creating another blockbuster efficacy vaccine just like ICT-107.
IMUC got an exceptionally good deal on this----get ready for additional news for upcoming trials.